LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse[S]

@article{Quinet2009LXRLL,
  title={LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse[S]},
  author={Elaine M. Quinet and Michael D. Basso and Anita R Halpern and David W. Yates and Robert J. Steffan and Val{\'e}rie Clerin and Christine Resmini and James C. Keith and Thomas J. Berrodin and Irene B. Feingold and Wenyan Zhong and Helen B. Hartman and Mark J. Evans and Stephen J. Gardell and Elizabeth A. DiBlasio-Smith and William M. Mounts and Edward R. Lavallie and Jay E. Wrobel and Ponnal Nambi and George P. Vlasuk},
  journal={Journal of Lipid Research},
  year={2009},
  volume={50},
  pages={2358 - 2370}
}
Liver X receptors (LXRs) are ligand-activated transcription factors that coordinate regulation of gene expression involved in several cellular functions but most notably cholesterol homeostasis encompassing cholesterol transport, catabolism, and absorption. WAY-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR−/− atherosclerosis model with no associated increase in hepatic… Expand
Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model
TLDR
Despite no beneficial effect on dyslipidemia, LXR activation promotes macrophage-to-feces RCT in Dyslipidemic hamsters, emphasizing the use of species with a more human-like lipoprotein metabolism for drug profiling. Expand
The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design.
TLDR
Future therapeutic strategies aiming to exert beneficial effects on cholesterol and glucose homeostasis, while circumventing the undesired effects on hepatic lipid metabolism, should target specific LXR-mediated processes. Expand
Macrophage-Independent Regulation of Reverse Cholesterol Transport by Liver X Receptors
TLDR
Unexpectedly, the studies suggest that the ability of macrophages to efflux cholesterol to HDL in vivo is not regulated by macrophage activity but is primarily determined by the quantity and functional activity of HDL. Expand
Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRα Activity and a Favorable Window in Nonhuman Primates
TLDR
BMS-779788, a partial LXRβ selective agonist, has decreased lipogenic potential compared with a full pan agonist in cynomolgus monkeys, with similar potency in the induction of genes known to stimulate RCT. Expand
Fucosterol is a selective liver X receptor modulator that regulates the expression of key genes in cholesterol homeostasis in macrophages, hepatocytes, and intestinal cells.
TLDR
The results suggest that fucosterol is a dual-LXR agonist that regulates the expression of key genes in cholesterol homeostasis in multiple cell lines without inducing hepatic triglyceride accumulation. Expand
Liver X receptors and fat cell metabolism
TLDR
It should be apparent that although LXR may impact on several different pathways in metabolism, the clinical role of LXR modulation in adipose tissue is still not clear. Expand
Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils.
TLDR
The effects of an LXR agonist on lipid and lipoprotein metabolism and neutrophils in human subjects are shown and the primate model markedly underestimated human lipogenic responses and did not predict human neutrophil effects. Expand
Liver X Receptors, Atherosclerosis and Inflammation
TLDR
Recent evidence is described that both highlights the key roles of LXRs in atherosclerosis and inflammation and provides novel insights into the mechanisms underlying their actions. Expand
Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics
TLDR
It is demonstrated that IMB-808 could act as an innovative partial LXR agonist that avoids common lipogenic side effects, providing insight for the design of novel LXR modulators. Expand
Differential regulation of gene expression by LXRs in response to macrophage cholesterol loading.
TLDR
Treatment of human THP-1 macrophages with endogenous or synthetic LXR ligands stimulates both transcriptional and posttranscriptional pathways that result in the selective recruitment of the LXRα subtype to LXR-regulated promoters, indicating a gene-selective response to cholesterol loading. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia*s⃞
TLDR
Evidence is provided that DMHCA is a strong candidate as therapeutic agent for the treatment or prevention of atherosclerosis, circumventing the negative side effects of other LXR agonists. Expand
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
TLDR
It is demonstrated here that the nonsteroidal LXR agonist GW3965 has potent antiatherogenic activity in two different murine models, providing direct evidence for an atheroprotective effect of LXRs agonists and support their further evaluation as potential modulators of human cardiovascular disease. Expand
Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE.
TLDR
Observations indicate that LXRalpha has an essential role in maintaining peripheral cholesterol homeostasis in the context of hypercholesterolemia and provide in vivo support for drug development strategies targeting LXRbeta. Expand
Synthetic LXR agonists increase LDL in CETP species Published, JLR Papers in Press, July 16, 2005. DOI 10.1194/jlr.M500116-JLR200
TLDR
Results in hamsters and cynomolgus monkeys reveal additional problems associated with current synthetic LXR agonists and emphasize the importance of profiling compounds in preclinical species with a more human-like LXR response and lipoprotein metabolism. Expand
Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE
TLDR
Treatment of mice with synthetic LXR ligand ameliorates the cholesterol overload phenotype and reduces atherosclerosis, indicating that LXRα has an essential role in maintaining peripheral cholesterol homeostasis in the context of hypercholesterolemia. Expand
T‐0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor‐deficient mice
TLDR
The results suggest that LXR ligands may be useful therapeutic agents for the treatment of atherosclerosis. Expand
Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor Published, JLR Papers in Press, August 1, 2004. DOI 10.1194/jlr.M400257-JLR200
TLDR
Cell-based studies indicate that DMHCA enhances cholesterol efflux in macrophages and suggest a mechanism whereby this selective modulator can potentially inhibit cholesterol accumulation, and may have application to the study and treatment of atherosclerosis. Expand
Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
TLDR
Liver X receptors operate as cholesterol sensors which protect from cholesterol overload by inhibiting intestinal cholesterol absorption, stimulating cholesterol efflux from cells to high-density lipoproteins, its transport to the liver, conversion to bile acids, and biliary excretion. Expand
Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
TLDR
Results suggest indazoles such as 13 may have an improved profile for potential use as a therapeutic agent, and the lack of TG effect of 13 correlated with its inability to increase liver fatty acid synthase (FAS) gene expression. Expand
Macrophage Liver X Receptor Is Required for Antiatherogenic Activity of LXR Agonists
TLDR
It is demonstrated that LXR agonist treatment increases ATP-binding cassette transporter expression within preexisting atherosclerotic lesions, resulting in regression of these lesions as well as remodeling from vulnerable to stable lesions and a reduction in macrophage content. Expand
...
1
2
3
4
5
...